On September 3, 2019 Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, reported the appointment of Shakti Narayan, J.D., Ph.D., as its Chief Executive Officer and a member of the Board of Directors (Press release, accent therapeutics, SEP 3, 2019, View Source [SID1234539233]). Dr. Narayan brings a strong record of experience in life sciences, having held various leadership roles which led to transformational achievements within both the biotechnology and pharmaceutical industries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Accent is defining a new and practical paradigm for addressing RNA pathobiology by targeting the proteins that control many aspects of RNA biology, unlocking the potential of RNA biology and providing new hope for patients," said Robert A. Copeland, Ph.D., President and Chief Scientific Officer of Accent. "We are delighted to welcome Shakti to Accent. He brings a wealth of biopharma experience and leadership as we advance our leading position in the field of RNA modification."

"Accent has made incredible progress developing a pipeline of targeted therapies in this novel area of biology and is well-positioned to accelerate its impact in the field," said Dr. Narayan. "I’m thrilled to be joining the exceptional team at Accent as we work to better the course of cancer treatment for patients."

Dr. Narayan was most recently Chief Business Officer of Tango Therapeutics, where he was responsible for business development, finance and various operational functions. During his tenure at Tango, he led a $1.7B transformational partnership with Gilead Sciences. Prior to Tango, Dr. Narayan was Vice President, Head of Transactions at Johnson & Johnson Innovation, where he helped build J&J’s Innovation Centers model, led oncology business development efforts and led a team of dealmakers who drove transactions for multiple J&J businesses. Prior to his time at J&J, Dr. Narayan led business development as part of the management team at Nodality, a VC-backed personalized medicine biotechnology company, where he developed the company’s partnering strategy, led and closed multiple strategic collaborations and held various operational roles.

Dr. Narayan’s career began in business development at Genentech and as a life sciences transactional attorney at Wilson Sonsini Goodrich & Rosati. Dr. Narayan earned his Bachelor of Arts in biology from Grinnell College, obtained his Ph.D. in cellular and molecular biology at the University of Wisconsin Madison and the Salk Institute and was a post-doctoral scientist at Stanford University. His legal studies were completed at the University of California Berkeley School of Law, where he earned a J.D.

On September 3, 2019 Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, reported presentations at the following investor conferences during the months of September and early October (Press release, Exicure, SEP 3, 2019, View Source [SID1234539232]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 21st Annual Global Investment Conference
Corporate update
Presented by: CEO David Giljohann
Monday, September 9, 2019 at 10:25am ET
Location: New York, NY
Ladenburg Thalmann 2019 Healthcare Conference
Corporate update
Presented by: CEO David Giljohann
Tuesday, September 24, 2019 at 1:30pm ET
Location: New York, NY
Chardan’s 3rd Annual Genetic Medicines Conference
Corporate update
Presented by: Dr. David Giljohann
Monday, October 7, 2019 at 2:00pm ET
Location: New York, NY

The Next Big Thing in Genetic Medicines
Panelist: Dr. David Giljohann
Tuesday, October 8, 2019 at 9:30am ET
Location: New York, NY
An audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.

On September 3, 2019 Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, reported that it has appointed Dr Soren Bregenholt as Chief Executive Officer (Press release, Macrophage Pharma, SEP 3, 2019, View Source [SID1234539231]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: "The Board is delighted to have attracted Søren to Macrophage Pharma. Soren’s outstanding track record from executive positions in both biotech and pharma, as well as his extensive expertise and insight in immunology, will be invaluable as we further develop and commercialise our proprietary Esterase Sensitive Motif (ESM) platform and evolve Macrophage Pharma into a leading biotech company."

Dr Søren Bregenholt, CEO of Macrophage Pharma, said: "I am excited to join Macrophage Pharma as CEO. The Company’s unique and proprietary ESM technology platform is a compelling strategy for inducing transcriptional reprofiling of monocytes and macrophages and represents a differentiated approach to modulation of a centrally important regulator of the immune response across a variety of human diseases. I look forward to working with management and Board to unlock the full therapeutic and commercial potential of the technology in both cancer and non-cancer fields."

Søren Bregenholt PhD is a Danish national with an extensive operational and strategic track record from the biotech and pharmaceutical industries. He previously held senior executive roles including COO and CBO at Danish biotech companies Symphogen and IO Biotech, respectively. As part of the global R&D Management at Novo Nordisk, Søren was responsible for the global R&D Strategy and External Innovation efforts. Currently, Søren serves as Chairman of the Board at the Danish-Swedish life science organization Medicon Valley Alliance. His academic career, at the University of Copenhagen and Institute Pasteur, Paris, has focussed on immunoregulation and immunopathology in cancer and other diseases.

On September 3, 2019 Selvita (WSE: SLV) reported that Pawel Przewiezlikowski, Chief Executive Officer, will present at the following conferences in New York (Press release, Selvita, SEP 3, 2019, View Source [SID1234539230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019
Location: Lotte New York Palace Hotel
Date/Time: Monday, Sept. 9, at 5:30 p.m. EDT
Webcast: A live and archived webcast of this presentation will also be made available at View Source

Event: Rambam Foundation Life Sciences Symposium, Sept. 10, 2019
Location: The YJP Mansion
Date/Time: Tuesday, Sept. 10, at 9:15 a.m. EDT

On September 3, 2019 OBI Pharma, a Taiwan biopharma company (TPEx: 4174), reported that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-999 to conduct a Phase 1/2 study of its antibody drug conjugate (ADC) cancer therapy targeting Globo H, a glycolipid antigen (Press release, OBI Pharma, SEP 3, 2019, View Source [SID1234539229]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OBI plans to enroll patients with advanced solid tumors including pancreatic, gastric, colorectal and esophageal cancers. OBI Pharma’s Chief Medical Advisor, Tillman Pearce, M.D. noted, "This clinical trial intends to verify the safety and preliminary efficacy profile of OBI-999, a novel first-in-class antibody-drug conjugate that selectively targets Globo H. We are delighted to conduct this first-in-human clinical trial at the University of Texas M.D. Anderson Cancer Center, one of America’s leading academic oncology research institutions."

Michael Chang, Ph.D., OBI Pharma Chairman and CEO, added, "OBI Pharma is excited to commence the Phase 1/2 safety and efficacy study of OBI-999, our unique anti-Globo H ADC glycolipid cancer therapy. We strive to develop and validate our novel anti-Globo H immuno-oncology pipeline to fulfill unmet medical needs of cancer patients."

About OBI-999

OBI-999 is a novel first-in-class Antibody Drug Conjugate (ADC) with a proprietary linker technology that provides a consistent Drug-to-Antibody ratio (DAR) for cancer treatment that is based on Globo H, an antigen expressed in up to 15 epithelial cancers. OBI-999 uses a Globo H antibody to target cancer cells of high Globo H expression. By releasing a small molecule chemotherapeutic drug through the specificity of the antibody, it directly deploys cytotoxic therapy at the targeted cancer cells. This Globo H targeting antibody, OBI-888, is currently in a Phase ½ clinical trial (ClinicalTrials.gov Identifier: NCT03573544) to test its safety and efficacy as an immune-oncology therapy. In pre-clinical xenograft animal models in multiple tumor types (pancreatic, lung, gastric, and breast), OBI-999 has demonstrated profound tumor shrinkage at various doses. In pre-clinical single and repeated dose toxicology studies, OBI-999 was well-tolerated, and achieved a favorable safety margin which warrants further clinical development. OBI Pharma owns global rights to OBI-999.